摘要
目的探讨沙库巴曲缬沙坦与布美他尼联合治疗慢性心力衰竭(CHF)患者的效果。方法选取息县人民医院2019年2月至2020年2月收治的120例CHF患者,以掷硬币法分为对照组和观察组,各60例。对照组接受基础治疗、缬沙坦联合布美他尼治疗;观察组接受基础治疗、沙库巴曲缬沙坦联合布美他尼治疗。两组均治疗3个月。比较两组治疗前、治疗3个月时心功能[左室舒张末期内径(LVEDD)、左室射血分数(LVEF)]、血清N末端B型利钠肽(NT-pro BNP);随访3个月,统计治疗期间患者出现的不良反应情况;随访12个月,记录患者再入院率情况。结果治疗3个月时,两组LVEDD值低于治疗前,LVEF值高于治疗前,且观察组LVEDD值低于对照组,LVEF值高于对照组(P<0.05);治疗3个月时,与治疗前比较,两组血清NT-pro BNP水平均降低,且观察组低于对照组(P<0.05);治疗期间,对照组与观察组的不良反应发生率比较,差异无统计学意义(P>0.05);随访12个月,与对照组相比,观察组因CHF再入院率较低(P<0.05)。结论应用沙库巴曲缬沙坦与布美他尼联合治疗CHF患者可改善其心功能,降低血清NT-pro BNP水平及再入院率。
Objective To investigate the effect of sacubitril valsartan combined with bumetanide in the treatment of patients with chronic heart failure(CHF).Methods One hundred and twenty patients with CHF treated in Xixian People’s Hospital from February 2019 to February 2020 were selected,a coin tossing method was used to divide them into control group and observation group,each with 60 cases.The control group was treated with basic treatment,valsartan and bumetanide,and the observation group was treated with basic treatment,sacubitril valsartan and bumetanide;all patients were treated for 3 months.Cardiac function[left ventricular end diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF)]and serum N-terminal B-type natriuretic peptide(NT-pro BNP)were compared between the two groups before and 3 months after treatment.The patients were followed up for 3 months,and the adverse reactions occurred during the treatment were analyzed.The readmission rate of patients was recorded after 12 months of follow-up.Results After 3 months of treatment,LVEDD value was lower and LVEF value was higher in both groups than those before treatment,and LVEDD value was lower and LVEF value was higher in the observation group than those in the control group(P<0.05).After 3 months of treatment,compared with before treatment,the serum NT-pro BNP level in both groups was decreased,and the observation group was lower when compared with the control group(P<0.05).During treatment,there was no difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).After 12 months of follow-up,compared with the control group,the readmission rate of CHF in the observation group was lower(P<0.05).Conclusion The treatment of sacubitril valsartan combined with bumetanide can improve cardiac function,reduce serum NT-pro BNP level and readmission rate in patients with CHF.
作者
刘永新
郑璐
何炳乐
LIU Yongxin;ZHENG Lu;HE Bingle(Department of Pharmacy,Xixian People’s Hospital,Xinyang 464300,China)
出处
《河南医学研究》
CAS
2021年第29期5490-5493,共4页
Henan Medical Research
